Kesmalea Therapeutics
PrivateLast Round
Series A
Extension
Nov 10, 2026
Total Funding Raised
$97.14M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Kesmalea Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A Extension round in November 2026.
Kesmalea Therapeutics is a biopharmaceutical company developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kesmalea Therapeutics Comparables
Compare Kesmalea Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dunad Therapeutics | 91% | |
| SEED Therapeutics | 88% | |
| Amphista Therapeutics | 86% |
For institutional investors. Book with your work email.
Kesmalea Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Nov 10, 2026 | ||||
| Series A | Sep 7, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kesmalea Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Syncona | Series A Extension, Series A |
| Oxford Science Enterprises | Series A, Series A Extension |
| 4BIO Capital | Series A Extension |
| Actium Group | Series A Extension |
| Mission BioCapital | Series A Extension |
| CE-Ventures | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2026
$60M round led by 4BIO Capital.
- May 4, 2025
Monthly visitors increased 1096% MoM, reaching 1.1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 11, 2026
On Nov 10th '26, Kesmalea receives $60M in Series A2 financing led by 4BIO Capital, with participation from new and existing investors, to advance its oral, brain-penetrant tau degrader into clinical development and continue developing its SELFTAC(R) platform.
- receives_financingNov 10, 2026
Kesmalea receives $6.69M (£5 million) in financing in 2023, following a £25 million Series A financing in 2022.
- receives_financingNov 10, 2026
Kesmalea receives $33.5M in Series A financing, with the evidence identifying a £25 million Series A in 2022 co-led by Syncona and Oxford Science Enterprises, followed by another £5 million in 2023.
For institutional investors. Book with your work email.
Kesmalea Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Kesmalea Therapeutics's valuation, stock price, and market status.
Is Kesmalea Therapeutics a public or private company?
Kesmalea Therapeutics is a private company.
What is the current stock price of Kesmalea Therapeutics?
Kesmalea Therapeutics is a private company, so its shares have no public market price. Caplight tracks Kesmalea Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Kesmalea Therapeutics worth (valuation)?
Valuation information for Kesmalea Therapeutics is not publicly available.
Can I buy Kesmalea Therapeutics stock?
Kesmalea Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Kesmalea Therapeutics's last funding round?
Kesmalea Therapeutics's most recent funding round was Series A Extension on November 10, 2026.
Who are the main investors in Kesmalea Therapeutics?
Key investors in Kesmalea Therapeutics include Syncona, 4BIO Capital.
Will Kesmalea Therapeutics IPO soon?
No public IPO plans have been announced for Kesmalea Therapeutics.
How can I track Kesmalea Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Kesmalea Therapeutics's shares on secondary markets.